HomePTX • ASX
add
Prescient Therapeutics Ltd
Previous close
$0.044
Day range
$0.042 - $0.044
Year range
$0.037 - $0.066
Market cap
36.53M AUD
Avg Volume
393.68K
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
Market news
Financials
Income Statement
Revenue
Net income
| (AUD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 624.21K | -35.64% |
Operating expense | 1.93M | -34.84% |
Net income | -1.22M | 32.33% |
Net profit margin | -196.17 | -5.13% |
Earnings per share | — | — |
EBITDA | -1.31M | 34.45% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (AUD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 8.41M | -54.41% |
Total assets | 16.58M | -33.04% |
Total liabilities | 934.79K | -56.56% |
Total equity | 15.65M | — |
Shares outstanding | 805.32M | — |
Price to book | 2.20 | — |
Return on assets | -19.69% | — |
Return on capital | -20.82% | — |
Cash Flow
Net change in cash
| (AUD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -1.22M | 32.33% |
Cash from operations | -2.89M | -66.14% |
Cash from investing | 1.00M | -50.00% |
Cash from financing | -148.11K | -1,732.02% |
Net change in cash | -2.05M | -885.92% |
Free cash flow | -805.50K | 31.59% |
About
Prescient Therapeutics Ltd is a clinical stage oncology company. The company is focused on the development of a universal CAR-T platform, enhanced CAR-T cell manufacturing & function and on two small molecule drug targeted therapies. Wikipedia
Founded
May 22, 1986
Website
Employees
3
